Vernal Keratoconjunctivitis MarketThe global Vernal Keratoconjunctivitis Market is expected to garner a market value of US$ 436.9 Million in 2023 and is expected to accumulate a market value of US$ 782.42 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. One of the reasons driving the global m.
Press Release Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today announced that Ben Bergo, co-founder and chief executive officer, will…
Even if your practice is pressed for time, you have time to diagnose dry eye disease, treat it and track your results. Diagnosis doesn’t take a lot of extra equipment — just simple steps you can fit into a basic exam.
Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Brimochol PF, a once-daily eye drop under evaluation for the treatment of presbyopia, achieved primary and secondary endpoints in the pivotal phase 3 BRIO-I clinical trial, according to a press release from Visus Therapeutics.